Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2025-02-18 Annual Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
2024 Annual Report & 20-F Information
Annual Report Classification · 100% confidence The document is explicitly titled 'AstraZeneca PLC Annual Report and Form 20-F Information 2024'. It contains comprehensive financial statements, a strategic report, corporate governance details, and auditor reports, which are the defining characteristics of an Annual Report (10-K). It is not an announcement of a report, but the report itself. FY 2024
2025-02-18 English
Directorate Change
Board/Management Information Classification · 98% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the RNS Number and the closing footer mentioning RNS and the London Stock Exchange. The core content explicitly details changes in the company's Board of Directors: proposing a new Non-Executive Director for election at the AGM, and announcing the retirement of two current Non-Executive Directors. This directly matches the definition for 'Board/Management Information' (MANG). Although it mentions the AGM, the primary focus is the director changes, not AGM materials (AGM-R) or voting results (DVA).
2025-02-18 English
FINAL RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting final results for the full year and Q4 2024. It contains detailed financial performance data including revenue, EPS, segment performance, guidance for FY 2025, and pipeline updates. The document includes comprehensive financial tables and management commentary on results and outlook. It is not merely an announcement of a report but contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and full year). However, since it is a Form 6-K (a report of foreign issuer to the SEC), and it includes quarterly and full year results, it aligns most closely with an Interim / Quarterly Report (IR) classification, as 6-Ks often serve as interim reports for foreign issuers. The document is too detailed and lengthy to be a simple earnings release or report publication announcement. Therefore, the best fit is Interim / Quarterly Report (IR).
2025-02-06 English
Final Results
Earnings Release Classification · 98% confidence The document explicitly states 'Full Year and Q4 2024 results' and provides detailed financial tables summarizing performance for 'FY 2024' and 'Q4 2024'. It includes revenue summaries, EPS figures, dividend declarations, and forward-looking guidance for FY 2025. This content structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the 'Full Year' results, it is more comprehensive than a typical quarterly release, but the format strongly aligns with the initial announcement of period results, often referred to as an Earnings Release (ER) in the US context, or a comprehensive results announcement. Given the detailed financial tables and CEO commentary, it is a primary results announcement. Since it covers the full year, it is often associated with the 10-K filing, but this document is clearly an announcement/press release format, not the full regulatory 10-K document itself. The presence of 'Full Year' results alongside Q4 results, presented in a press release style, points towards an Earnings Release (ER) which summarizes the annual performance, or potentially an Interim Report (IR) if the company typically uses this format for its annual summary announcement before the 10-K. However, the structure is most typical of an Earnings Release (ER) announcing the key figures for the period, even if that period is the full year. The document also mentions a conference call and provides a reporting calendar, confirming its nature as a results announcement. FY 2024
2025-02-06 English
Earnings Release 2024
Earnings Release Classification · 100% confidence The document is a comprehensive financial report titled 'Full Year and Q4 2024 results' for AstraZeneca. It contains detailed financial tables, management commentary, guidance, pipeline updates, and sustainability highlights. It is not an announcement of a report (RPA) because it contains the full content of the results themselves. It is not a 10-K as it is a quarterly/annual results release, and it is not a call transcript. It fits the definition of an Earnings Release (ER) as it is the initial announcement of the period's financial results, including key highlights, guidance, and performance metrics. FY 2024
2025-02-06 English
Regulatory Filings 2025
Regulatory Filings
2025-02-06 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.